108 related articles for article (PubMed ID: 18501519)
1. Advances in the treatment of non-small cell lung cancer.
Saijo N
Cancer Treat Rev; 2008 Oct; 34(6):521-6. PubMed ID: 18501519
[TBL] [Abstract][Full Text] [Related]
2. Gefitinib or erlotinib in the treatment of advanced non-small cell lung cancer.
Shao YY; Lin CC; Yang CH
Discov Med; 2010 Jun; 9(49):538-45. PubMed ID: 20587343
[TBL] [Abstract][Full Text] [Related]
3. Gefitinib in advanced non-small cell lung cancer: does it deserve a second chance?
Stinchcombe TE; Socinski MA
Oncologist; 2008 Sep; 13(9):933-44. PubMed ID: 18784157
[TBL] [Abstract][Full Text] [Related]
4. Gefitinib compared with systemic chemotherapy as first-line treatment for chemotherapy-naive patients with advanced non-small cell lung cancer: a meta-analysis of randomised controlled trials.
Wang F; Wang LD; Li B; Sheng ZX
Clin Oncol (R Coll Radiol); 2012 Aug; 24(6):396-401. PubMed ID: 22019482
[TBL] [Abstract][Full Text] [Related]
5. Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating Epidermal Growth Factor Receptor mutation: implications for clinical practice and open issues.
Gridelli C; De Marinis F; Di Maio M; Cortinovis D; Cappuzzo F; Mok T
Lung Cancer; 2011 Apr; 72(1):3-8. PubMed ID: 21216488
[TBL] [Abstract][Full Text] [Related]
6. A review of the benefit-risk profile of gefitinib in Asian patients with advanced non-small-cell lung cancer.
Park K; Goto K
Curr Med Res Opin; 2006 Mar; 22(3):561-73. PubMed ID: 16574039
[TBL] [Abstract][Full Text] [Related]
7. Gefitinib for the treatment of non-small-cell lung cancer.
Campbell L; Blackhall F; Thatcher N
Expert Opin Pharmacother; 2010 Jun; 11(8):1343-57. PubMed ID: 20426712
[TBL] [Abstract][Full Text] [Related]
8. Combined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutations.
Morita S; Okamoto I; Kobayashi K; Yamazaki K; Asahina H; Inoue A; Hagiwara K; Sunaga N; Yanagitani N; Hida T; Yoshida K; Hirashima T; Yasumoto K; Sugio K; Mitsudomi T; Fukuoka M; Nukiwa T
Clin Cancer Res; 2009 Jul; 15(13):4493-8. PubMed ID: 19531624
[TBL] [Abstract][Full Text] [Related]
9. Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy.
Kim ST; Uhm JE; Lee J; Sun JM; Sohn I; Kim SW; Jung SH; Park YH; Ahn JS; Park K; Ahn MJ
Lung Cancer; 2012 Jan; 75(1):82-8. PubMed ID: 21684626
[TBL] [Abstract][Full Text] [Related]
10. [Erlotinib. A new option for non-small cell lung cancer].
Polk B
Med Monatsschr Pharm; 2006 Jan; 29(1):4-6. PubMed ID: 16463547
[No Abstract] [Full Text] [Related]
11. Erlotinib: small-molecule targeted therapy in the treatment of non-small-cell lung cancer.
Smith J
Clin Ther; 2005 Oct; 27(10):1513-34. PubMed ID: 16330289
[TBL] [Abstract][Full Text] [Related]
12. Gefitinib in the treatment of advanced non-small-cell lung cancer.
Reck M
Expert Rev Anticancer Ther; 2009 Apr; 9(4):401-12. PubMed ID: 19374595
[TBL] [Abstract][Full Text] [Related]
13. Gefitinib (Iressa, ZD1839): a novel targeted approach for the treatment of solid tumors.
Von Pawel J
Bull Cancer; 2004 May; 91(5):E70-6. PubMed ID: 15582898
[TBL] [Abstract][Full Text] [Related]
14. Gefitinib does not increase survival in lung cancer patients.
Golsteyn RM
Drug Discov Today; 2005 Mar; 10(6):381. PubMed ID: 15808815
[No Abstract] [Full Text] [Related]
15. Erlotinib in non-small cell lung cancer treatment: current status and future development.
Gridelli C; Bareschino MA; Schettino C; Rossi A; Maione P; Ciardiello F
Oncologist; 2007 Jul; 12(7):840-9. PubMed ID: 17673615
[TBL] [Abstract][Full Text] [Related]
16. Gefitinib in patients with non-small cell lung cancer: symptomatic improvement within a few days.
Bearz A; Vaccher E; Spazzapan S; Berretta M; Tirelli U
Lung Cancer; 2005 Sep; 49(3):417-8. PubMed ID: 16102608
[No Abstract] [Full Text] [Related]
17. Gefitinib (ZD1839, Iressa) in non-small-cell lung cancer: a review of clinical trials from a daily practice perspective.
Barlési F; Tchouhadjian C; Doddoli C; Villani P; Greillier L; Kleisbauer JP; Thomas P; Astoul P
Fundam Clin Pharmacol; 2005 Jun; 19(3):385-93. PubMed ID: 15910663
[TBL] [Abstract][Full Text] [Related]
18. Economic analysis: randomized placebo-controlled clinical trial of erlotinib in advanced non-small cell lung cancer.
Bradbury PA; Tu D; Seymour L; Isogai PK; Zhu L; Ng R; Mittmann N; Tsao MS; Evans WK; Shepherd FA; Leighl NB;
J Natl Cancer Inst; 2010 Mar; 102(5):298-306. PubMed ID: 20160168
[TBL] [Abstract][Full Text] [Related]
19. Development of the novel biologically targeted anticancer agent gefitinib: determining the optimum dose for clinical efficacy.
Wolf M; Swaisland H; Averbuch S
Clin Cancer Res; 2004 Jul; 10(14):4607-13. PubMed ID: 15269131
[TBL] [Abstract][Full Text] [Related]
20. Targeting the epidermal growth factor receptor in non-small cell lung cancer.
Herbst RS; Bunn PA
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5813-24. PubMed ID: 14676101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
